For decades, psychedelic drugs like LSD, psilocybin (magic mushrooms), and cannabis have been associated with societal outliers, hedonism, and general recklessness. But research into psychedelics has come a long way, and biotech companies aiming to harness the therapeutic potential of psychedelics are proliferating.

Disruptive biotech companies developing cell and gene therapies (CGT) and other precision medicines remain imperative for industry evolution, and specifically, Contract Development Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) will play a critical role in the coming years.

To date the platform model has wildly garnered private investment and IPO launches, as well as enticed talent.

While most of the funding for biotech startups developing novel therapeutics has stalled in the past year as VCs take a more conservative approach and focus on companies already generating revenue through multiple streams, demand for therapies has not decreased.

Over the last decade, professionals working in the Life Sciences understand that change has been the only constant.

It wasn’t long ago when the term “artificial intelligence” (AI) conjured up images of hyper realistic human robots or flying cars.

With much of biotech news focusing on a down market and several prominent companies having recently failed to hit primary endpoints, it begs the question…

The word ‘protein’ often makes one think of a steak dinner or a smoothie, but in the world of biotech protein therapeutics are forming the backbone of next-generation therapies and novel medicines…

Synthetic biology is a new area of research and development that applies engineering principles to biological processes. Synthetic biology enables…